More means more. In a world where anyone can make claims, only taXonomy Pathways makes claims interoperable. That’s the difference between simply collecting data and creating evidence that is complete, verifiable, and ready to power critical decisions before the year is over.
As Q4 budgets come under the familiar “use it or lose it” pressure, the race to close evidence gaps is on. With taXonomy Pathways, you can accelerate timelines and answer unanswered questions by combining the most relevant data types for each therapeutic area. HealthVerity taXonomy is the most comprehensive, consistent, and curated claims resource, interoperable with labs, EHR, and more in purpose-built therapy areas. Closed claims provide the foundation, but the real acceleration comes when you enrich that base with EHR, clinical notes, labs, or imaging data to reveal insights your competitors will miss. This is where taXonomy Pathways enters the picture.
Here are the top ways taXonomy Pathways can help you close the gap before year end, with specific therapy areas that show how combining closed claims with EHR, labs, notes, and even imaging demonstrates how interoperable data truly means more evidence.
For conditions like coronary artery disease (CAD), congestive heart failure (CHF), pulmonary hypertension, and pulmonary arterial hypertension, the foundation begins with closed claims. Adding EHR and clinical notes reveals treatment decisions and disease progression, while labs provide biomarkers and imaging captures measures such as ejection fraction. Together, this pathway delivers a clearer view of burden of care, treatment persistence, and safety outcomes.
In obesity, type 2 diabetes, diabetic neuropathy, and NASH/MASH, closed claims establish the baseline, but differentiation comes from EHR and notes that capture GLP-1 initiation, comorbidity progression, and adverse events. Repeated measures of BMI, height, weight, and blood pressure over time provide additional clinical context to track disease progression and response to treatment.Labs such as A1c or lipid panels bring precision, creating actionable evidence for HEOR.
For chronic kidney disease (CKD), C3G, and IgAN, closed claims alone fall short of staging or diagnostic clarity. Enriching with EHR, clinical notes, and targeted labs such as eGFR produces interoperable evidence that supports trial feasibility and post-market surveillance.
In conditions like mild cognitive impairment (MCI), dementia, Alzheimer’s, Parkinson’s, multiple sclerosis, generalized myasthenia gravis, and spinal muscular atrophy, closed claims provide scale but miss early signals of onset or decline. Enriching with EHR notes, lab markers, and imaging ensures more reliable diagnostic pathways and reduces uncertainty in feasibility and outcomes research.
Oncology research demands both breadth and granularity. For solid and liquid tumors such as NSCLC, breast, colorectal, prostate, NHL, and leukemias (ALL, AML, CML), closed claims supply longitudinal scale. EHR and notes add staging, grading, and adverse events, labs contribute molecular or genomic validation, and imaging, which is often difficult to access, adds critical context by showing the results of procedures and helping confirm both diagnosis and prognosis. This interoperability delivers insights not possible with siloed datasets.
As our clients know, customizable disease-level datasets are one of the fastest ways to transform leftover budget into 2025-ready evidence. taXonomy Pathways was designed for this moment: to close evidence gaps quickly, reduce procurement friction, and deliver interoperable insights that stand up to regulatory and payer scrutiny.
Don’t miss our webinar on taXonomy Pathways: “Closing the evidence gap before year end.” Watch the webinar to see how more really does mean more.